دورية أكاديمية
Premature Ovarian Insufficiency After Coronavirus Disease 2019 (COVID-19): Autoimmune Follicle-Stimulating Hormone (FSH) and FSH Receptor Blockade.
العنوان: | Premature Ovarian Insufficiency After Coronavirus Disease 2019 (COVID-19): Autoimmune Follicle-Stimulating Hormone (FSH) and FSH Receptor Blockade. |
---|---|
المؤلفون: | Stern R; New York Medical College, the Department of Obstetrics and Gynecology, New York Medical College, and Reproductive Endocrinology, Westchester Medical Center, Valhalla, and Westmed Reproductive Services, Purchase, New York., Bibi M, Keltz MD |
المصدر: | Obstetrics and gynecology [Obstet Gynecol] 2024 Jun 01; Vol. 143 (6), pp. e149-e152. Date of Electronic Publication: 2024 Apr 05. |
نوع المنشور: | Case Reports; Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401101 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-233X (Electronic) Linking ISSN: 00297844 NLM ISO Abbreviation: Obstet Gynecol Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2004- : Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: New York. |
مواضيع طبية MeSH: | COVID-19*/immunology , COVID-19*/complications , Primary Ovarian Insufficiency*/immunology , Primary Ovarian Insufficiency*/drug therapy , Receptors, FSH*/antagonists & inhibitors , SARS-CoV-2*/immunology, Adult ; Female ; Humans ; Betacoronavirus ; Coronavirus Infections/immunology ; Coronavirus Infections/complications ; Coronavirus Infections/drug therapy ; Follicle Stimulating Hormone/blood ; Pandemics ; Pneumonia, Viral/immunology ; Pneumonia, Viral/complications ; Pneumonia, Viral/drug therapy |
مستخلص: | Background: Since the onset of the coronavirus disease (COVID-19) pandemic, a variety of long-COVID-19 symptoms and autoimmune complications have been recognized. Cases: We report three cases of autoimmune premature poor ovarian response in patients aged 30-37 years after mild to asymptomatic COVID-19 before vaccination, with nucleotide antibody confirmation. Two patients failed to respond to maximum-dose gonadotropins for more than 4 weeks, despite a recent history of response before having COVID-19. After a month of prednisone 30 mg, these two patients had normal follicle-stimulating hormone (FSH) levels, high oocyte yield, and blastocyst formation in successful in vitro fertilization cycles. All three patients have above-average anti-müllerian hormone levels that persisted throughout their clinical ovarian insufficiency. Two patients had elevated FSH levels, perhaps resulting from FSH receptor blockade. One patient, with a history of high response to gonadotropins 75 international units per day and below-normal FSH levels, had no ovarian response to more than a month of gonadotropins (525 international units daily), suggesting autoimmune block of the FSH glycoprotein and possible FSH receptor blockade. Conclusion: Auto-antibody production in response to COVID-19 before vaccination may be a rare cause of autoimmune poor ovarian response. Although vaccination is likely protective, further study will be required to evaluate the effect of vaccination and duration of autoimmune FSH or FSH receptor blockade. Competing Interests: Financial Disclosure The authors did not report any potential conflicts of interest. (Copyright © 2024 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.) |
References: | Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A, Kanduc D, et al. COVID-19 and autoimmunity. Autoimmun Rev 2020;19:102597. doi: 10.1016/j.autrev.2020.102597. (PMID: 10.1016/j.autrev.2020.102597) Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun 2021;12:5417. doi: 10.1038/s41467-021-25509-3. (PMID: 10.1038/s41467-021-25509-3) Cabral-Marques O, Halpert G, Schimke LF, Ostrinski Y, Vojdani A, Baiocchi GC, et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat Commun 2022;13:1220. doi: 10.1038/s41467-022-28905-5. (PMID: 10.1038/s41467-022-28905-5) Li K, Chen G, Hou H, Liao Q, Chen J, Bai H, et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. Reprod Biomed Online 2021;42:260–7. doi: 10.1016/j.rbmo.2020.09.020. (PMID: 10.1016/j.rbmo.2020.09.020) Phelan N, Behan LA, Owens L. The impact of the COVID-19 pandemic on women's reproductive health. Front Endocrinol 2021;12:642755. doi: 10.3389/fendo.2021.642755. (PMID: 10.3389/fendo.2021.642755) Wilkins J, Al-Inizi S. Premature ovarian insufficiency secondary to COVID-19 infection: an original case report. Int J Gynaecol Obstet 2021;154:179–80. doi: 10.1002/ijgo.13719. (PMID: 10.1002/ijgo.13719) Madaan S, Jaiswal A, Kumar S, Talwar D, Halani D. Premature ovarian failure: a long COVID sequelae. Med Sci 2021:25:1286–90. Puca E, Puca E. Premature ovarian failure related to SARS-CoV-2 infection. J Med Cases 2022;13:155–8. doi: 10.14740/jmc3791. (PMID: 10.14740/jmc3791) Ghanei M, Solaymani-Dodaran M, Qazvini A, Ghazale AH, Setarehdan SA, Saadat SH, et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respir Res 2021;22:245. doi: 10.1186/s12931-021-01833-6. (PMID: 10.1186/s12931-021-01833-6) Chaudhuri D, Sasaki K, Karkar A, Sharif S, Lewis K, Mammen MJ, et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med 2021;47:521–37. doi: 10.1007/s00134-021-06394-2. (PMID: 10.1007/s00134-021-06394-2) Goel N, Goyal N, Nagaraja R, Kumar R. Systemic corticosteroids for management of “long-COVID”: an evaluation after 3 months of treatment. Monaldi Arch Chest Dis 2021;92. doi: 10.4081/monaldi.2021.1981. (PMID: 10.4081/monaldi.2021.1981) Utrero-Rico A, Ruiz-Ruigómez M, Laguna-Goya R, Arrieta-Ortubay E, Chivite-Lacaba M, González-Cuadrado C, et al. A short corticosteroid course reduces symptoms and immunological alterations underlying long-COVID. Biomedicines 2021;9:1540. doi: 10.3390/biomedicines9111540. (PMID: 10.3390/biomedicines9111540) |
المشرفين على المادة: | 9002-68-0 (Follicle Stimulating Hormone) 0 (Receptors, FSH) |
تواريخ الأحداث: | Date Created: 20240404 Date Completed: 20240516 Latest Revision: 20240614 |
رمز التحديث: | 20240615 |
DOI: | 10.1097/AOG.0000000000005574 |
PMID: | 38574363 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1873-233X |
---|---|
DOI: | 10.1097/AOG.0000000000005574 |